Algeta Schedules Third Quarter 2013 Results Presentation,

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Algeta Schedules Third Quarter 2013 Results Presentation, Webcast and Conference Call

OSLO, Norway, Oct. 28, 2013 (GLOBE NEWSWIRE) --

Algeta ASA (OSE: ALGETA), a company focused on the development of novel targeted cancer therapeutics, will announce its third quarter 2013 results on Wednesday, 6 November 2013. A presentation by members of Algeta's executive management team to investors, analysts and the press will take place in Oslo at 10:00 CET. The presentation will also be webcast live and can be accessed through www.algeta.com where questions can also be submitted during the presentation. The presentation will take place at 10:00 CET at: KS-Agenda Møtesenter Haakon VIIs gate 9 0161 Oslo Norway. At 14:30 CET/08:30 Eastern Time, Algeta's executive management team will also host an international conference call. To participate in the conference call, please dial the appropriate number below five minutes prior to the call: US: +1 877 423 0830 UK: +44 20 7153 9154 Norway: +47 21 06 61 13 Sweden: +46 8-506 443 86 Denmark: +45 32 71 42 62 Switzerland: +41 44 580 65 22 Participant pin code: 873878# To access the replay, please dial: US: +1 877 679 2989 UK: +44 203 364 5200 Norway: +47 23 50 02 03 Sweden: +46 8-505 564 73 Conference reference: 348995# A replay of the conference call will also be available at www.algeta.com . The results report and the presentation will be available at www.algeta.com in the Investors section from 07:00 CET. ### For further information, please contact: Mike Booth +1 646 410 1884 Communications & Corporate Affairs ir@algeta.com Media enquiries: Mark Swallow +44 207 638 9571 Citigate Dewe Rogerson mark.swallow@citigatedr.co.uk Knut Ekern +47 22 04 82 00 Gambit Hill & Knowlton knut.ekern@hkstrategies.com Kari Watson +1 781 235 3060 MacDougall Biomedical Communications kwatson@macbiocom.com Investor enquiries: Tricia Truehart +1 646 378 2953 The Trout Group ttruehart@troutgroup.com About Algeta Algeta is a company focused on developing, manufacturing and marketing novel targeted therapies for patients with cancer. The Company is headquartered in Oslo, Norway, and has a US subsidiary, Algeta US, LLC, based in Cambridge, MA performing commercial marketing operations in the US. Algeta is listed on the Oslo Stock Exchange (Ticker: ALGETA). For more information please visit www.algeta.com . Press release: http://hugin.info/134655/R/1738456/583160.pdf [HUG#1738456]

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Celltrion's ZYMFENTRA Shows Efficacy in Crohn's Disease Study

Updated Category News Views 203

Celltrion's ZYMFENTRA® Demonstrates Efficacy in Crohn's Disease Celltrion, Inc. has recently published promising results from a post-hoc analysis of the LIBERTY-CD study regarding ZYMFENTRA® (infliximab-dyyb). This analysis reveals significant findings about the efficacy of ZYMFENTRA in treating Crohn's disease (CD), regardless of disease location, and it's exciting...

Continue Reading
Akamai Hits Major Milestone with FedRAMP High Ready Status

Updated Category News Views 232

Akamai Cloud Achieves FedRAMP High Ready Status CAMBRIDGE, Mass. – Akamai Technologies, Inc. (NASDAQ: AKAM), a leader in cybersecurity and cloud computing, has proudly announced its recent achievement of the FedRAMP High Ready status. This vital milestone confirms that Akamai is fully prepared to offer federal agencies cloud services that comply with the most rigorous...

Continue Reading
Sam Bankman-Fried's Letter: Claims, Allegations, and Future Hopes

Updated Category News Views 161

Sam Bankman-Fried's Explosive Revelations About FTX In a recently penned letter, former FTX founder Sam Bankman-Fried expressed a firm belief that FTX was never truly insolvent. He attributed much of the downfall of what he called a "$136 billion enterprise" to mismanagement by attorneys, laying blame for the financial struggles on those who were supposed to provide legal...

Continue Reading
Kraus Hamdani Aerospace's K1000ULE Unveils New Heights in UAVs

Updated Category News Views 151

Kraus Hamdani Aerospace's K1000ULE Achieves Remarkable Milestone Kraus Hamdani Aerospace, an innovator in autonomy and AI-driven unmanned systems, has announced the inclusion of its K1000ULE UAS in the U.S. Department of Defense's trusted Blue UAS Cleared List and Select List. This recognition marks a significant achievement in the field of unmanned aerial vehicles,...

Continue Reading
VNA & PACS Market Set to Reach $7.92 Billion by 2030

Updated Category News Views 280

Understanding the Vendor Neutral Archive (VNA) & PACS Market Growth The Vendor Neutral Archive (VNA) and Picture Archiving and Communication System (PACS) market is entering an exciting growth phase. This market, valued at approximately US$4.62 billion recently, is predicted to experience a significant uptick as it is forecasted to expand at a remarkable compound annual...

Continue Reading